Nā kukui ʻōmaʻomaʻo o NMPA Repotrectinib: He au hou no nā puʻupuʻu paʻa NTRK Fusion-Positive

I ka hoʻomaka ʻana o 2026, ua hoʻokō ka ʻoihana lapaʻau oncology o Kina i kahi holomua nui. Ma Ianuali 5, ua ʻae kūhelu ka China National Medical Products Administration (NMPA) i ka lāʻau lapaʻau hanauna hou ʻo Repotrectinib no ka mālama ʻana i nā maʻi makua me nā ʻōpū paʻa e hūnā ana i nā hui gene neurotrophic tyrosine receptor kinase (NTRK). Lawe mai kēia ʻae i ka manaʻolana hou a me nā koho i nā maʻi ʻōpū paʻa holomua e kū nei i nā pilikia lapaʻau, ʻoiai ka poʻe i hāʻule i nā lāʻau lapaʻau mua a i ʻole nele i nā koho lapaʻau kūpono.

3e5522cf7bfb8ac1ef73015acccfb3d6.jpg

**E pili ana iā Ocapler® (Repotrectinib): He Lāʻau Lapaʻau Hanauna Hou, Mana, a Pololei**

ʻO Ocapler® (Repotrectinib) kahi mea hoʻopaʻa tyrosine kinase hanauna hou (TKI) i hoʻolālā kūikawā ʻia e kuhikuhi pololei i nā hui ʻana o nā gene oncogenic ROS1 a me NTRK. No nā poʻe maʻi me nā puʻupuʻu paʻa (me ka maʻi kanesa māmā ʻaʻole liʻiliʻi, a pēlā aku) e lawe ana i kēia mau hoʻololi genetic, hōʻike ʻo Repotrectinib i ka pono koʻikoʻi ma hope o ke kūʻē ʻana i nā lāʻau lapaʻau i kuhikuhi mua ʻia. Hoʻomalu maikaʻi hoʻi ia i nā metastases o ka lolo, e hāʻawi ana i nā pono lapaʻau lōʻihi.

**ʻIkepili Paʻa e Hōʻike ana i ka Pono Kūikawā**

Ua hoʻokumu ʻia ka ʻāpono ʻana o ka NMPA ma ka haʻawina koʻikoʻi honua o ka Phase 1/2 TRIDENT-1. He mea hoʻoikaika nā hopena:

- **No nā poʻe maʻi i mālama mua ʻia me ka lāʻau lapaʻau i kuhikuhi ʻia iā TRK:** Ua hōʻea ka helu pane pahuhopu (ORR) i 50%, me ka helu kaohi maʻi (DCR) o 42%.
- **No nā poʻe maʻi i hoʻomaka mua i ka mālama ʻana i ka lāʻau lapaʻau i mālama ʻole ʻia me ka lāʻau lapaʻau i kuhikuhi ʻia e TRK:** ʻOi aku ka kupaianaha o ka pono, me ka helu pane kūʻokoʻa e like me 58%, me ka helu pane piha (CR) o 15%, ʻo ia hoʻi ua nalowale loa nā puʻupuʻu i kekahi mau maʻi. ʻO ka mea nui, ua hoʻomau ka 83% o ka poʻe pane i ka pōmaikaʻi i hoʻokahi makahiki ma hope.

Hōʻike maopopo kēia mau ʻikepili i ka hana anti-tumor ikaika a paʻa hoʻi o Repotrectinib, me kahi ʻano palekana e hiki ke hoʻokele ʻia, i nā poʻe maʻi me nā tumors paʻa NTRK fusion-positive.

**Ke Keʻena Hoʻokele Honua o ka Halemai Oncology o ka ʻĀpana Hema o Beijing: Kou Puka i ka Mālama Ola Honua**

Ma ke ʻano he hoʻokahi o nā kikowaena ʻike a me ka mālama ʻana i ka oncology ma Kina, aia mau ka Beijing South Region Oncology Hospital International Department ma ke alo o ke kaua ʻana i ka maʻi kanesa. ʻO ka International Medical Department kā mākou puka makani i hoʻolaʻa ʻia no nā poʻe maʻi mai ka honua holoʻokoʻa, i hoʻolaʻa ʻia e hāʻawi i nā lawelawe lapaʻau pilikino kiʻekiʻe e kūlike me nā kūlana honua.

**No ke aha e koho ai iā mākou?**

1. **Ke komo ʻana i nā lāʻau lapaʻau ʻoi loa o ka honua:** Ke hahai pono nei mākou i nā ʻae lāʻau lapaʻau honua hou loa (e like me ka ʻae hou ʻana o Repotrectinib), e hōʻoia ana e hiki i nā mea maʻi o ka honua ke komo i nā koho lapaʻau holomua ma Kina i kūlike me nā mea i loaʻa ma ʻAmelika Hui Pū ʻIa, ʻEulopa, a me nā wahi ʻē aʻe.
2. **Hui Loea Multidisciplinary (MDT):** Loaʻa iā mākou kahi hui loea akamai i nā ʻano ʻano puʻupuʻu paʻa like ʻole, me ke kanesa māmā, sarcoma, a me ke kanesa thyroid, hiki ke hāʻawi i ka ʻike pololei a me ka hoʻolālā lapaʻau piha no nā poʻe maʻi me nā hui gene kakaikahi e like me NTRK.
3. **Nā Lawelawe Maʻi Honua Hoʻokahi-Kū:** Mai ke kūkākūkā mua ʻana, ka loiloi moʻolelo lapaʻau, ka hoʻonohonoho ʻana i nā manawa, a me nā kūkākūkā loea a hiki i nā hoʻonohonoho lapaʻau, ke kākoʻo hoʻokipa ʻana i ka haukapila, a me ka mālama ʻana ma hope, hāʻawi mākou i nā lawelawe maʻalahi, ʻōlelo ʻōlelo, a me ka mālama pono ma ke kaʻina holoʻokoʻa.
4. **Hoʻonohonoho Lapaʻau Kūwaho Kūpono:** Hoʻomaopopo nui mākou i nā pono huakaʻi a me ke kamaʻilio ʻana o nā poʻe maʻi o ka honua a hiki ke hāʻawi i ke kōkua e pono ai e hōʻoia i ka maʻalahi a me ka hopohopo ʻole o kāu huakaʻi lapaʻau.

**E leka uila mai iā mākou i kēia manawa e hoʻomaka i kāu huakaʻi lapaʻau kikoʻī**

Inā ʻoe a i ʻole kāu poʻe aloha e ʻimi nei i ka manaʻolana hou no ka mālama ʻana i nā ʻōpū paʻa NTRK fusion-positive, e ʻoluʻolu e kelepona koke mai iā mākou. Ua mākaukau ka hui ʻoihana o kā mākou Keʻena Lapaʻau Honua e loiloi i kou kūpono a hāʻawi i nā alakaʻi lapaʻau kikoʻī.

- **Kaʻina Hana no nā mea maʻi honua:** 400-880-3716
- **WeChat/WhatsApp:** +86 17801183037 (WeChat ID: 17801183037)
- **Leka uila:**
100085_010@163.com
myimmnet@163.com

*(E ʻoluʻolu e hoʻomaopopo: No ka hōʻoia ʻana i ka pono o ke kamaʻilio ʻana, i ka wā e hoʻouna ai i nā moʻolelo lapaʻau, e ʻoluʻolu e kope i nā leka uila ʻelua a hoʻokomo i kahi wehewehe pōkole o ke kūlana.)*

**Manaʻo Hana:**
E ʻoluʻolu e hoʻomākaukau i nā hōʻike pathological pili, nā hōʻike hoʻāʻo genetic (ʻoi aku hoʻi nā mea i loaʻa nā hopena fusion gene NTRK), a me nā moʻolelo lapaʻau mua e hāʻawi i ka wā e hoʻokaʻaʻike mai ai iā mākou. E kōkua kēia i kā mākou poʻe loea e hana i kahi loiloi mua wikiwiki a pololei.

Ua kūpaʻa ka ʻOihana Hoʻokele o ka Halemai Oncology o ka ʻĀpana Hema o Beijing i ka mālama ʻana i ke olakino a me ke ola o nā maʻi ma ka honua holoʻokoʻa me ka ʻike loea lapaʻau a me ka mālama aloha a mehana. Ke kakali nei mākou i kāu nīnau.

微信图片_20241115181717


Ka manawa hoʻouna: Ian-08-2026